11/3/2026

speaker
Shari
Conference Call Operator

Ladies and gentlemen, welcome to the Q32026 earnings conference call. I am Shari, the course call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dr. Claus Rettig, Interim CEO. Please go ahead.

speaker
Dr. Claus Rettig
Interim Chief Executive Officer

Yes, good morning and welcome to our Q3 earnings conference call for the first time from our new Ad Office here in Athens. and thank you everybody for joining today. So, given we are in a new executive board set up since the end of August, let me start with a few words about myself. For many of you, I hope, I am a familiar face by now, but let me give you a little bit of background. So, I am a chemist by education and joined Evonik more than 35 years ago. I worked in several leadership positions in Germany, South Africa, Japan and Singapore over the time. For the last four years, I am heading the Asia region and have been an associated member of the Equonic Executive Board. I also served as an interim CFO from September 2025 until beginning of May 2026. And my start as an interim CEO was therefore Let's call it very smooth from my point of view. So we have a very competent and well-working management team. While Christian Kullmann is recovering from his surgery, there is absolutely no standstill here at Libonix. We continue to execute our strategy with full speed. Before we come to the strategy execution and our excellent financial performance in the Q3, a few words on the BASF takeover situation. As you know, we have decided not to enter into negotiations with BASF on the basis on the information we have received so far. That said, we will engage in a purely informational and confidential exchange with BASF in order to explain our position and to give them the opportunity to outline their rationale and the key consideration underlying their interest. Please understand that we will not comment any further, also not during today's Q&A session. We remain fully focused on our strategic direction and our development as an independent company. I will demonstrate now by laying out our roadmap to our most important midterm goal of achieving return on capital employed of around 11% by 2029. Michael will then comment on our continuous strong operating performance in Q3. And then we'll end the presentation with the outlook for this year. In the next three years, we will shape Evonik into a different company. A company that is much more focused on its core, that is much more agile, and that in the end, latest by 2029, will earn more than its cost of capital. That is something that not many companies in our sectors will achieve. I can only refer you to a survey at some recently showing that only one in five companies in the chemical industry is earning cost of capital today. And we are highly confident that we will get there. This confidence is backed by tangible measures, a lot of them. We are looking at return on capital more holistically now. On top of the equation stands the increase in earnings in form of adjusted EBIT. That is not new. The existing strong emphasis on growth and efficiency will continue. The same strict focus is now on the denominator, aiming at the reduction of capital employed. We will show you the enhanced focus on capex and networking capital for the coming years in a minute. Almost as important, the whole management team is What we call laser focus this time on execution. By launching portfolio change, by driving the robotic tailor-made, and by investing into new solutions and sites, we have in the last years laid the foundation for strong financial success. Now is the time to take financial final execution steps and to harvest the results. Our strong performance in 2026 with return on capital employed gaining more than 2 percentage points shows us that we are moving into the right direction. I will not go through all the slides that we have prepared for you today, but will only highlight one example for each of the five return on capital employed levers. The most important lever is growth. The company has to grow to be successful in the long run. This is currently not easy in chemicals, as you know, but it can be done. And we see it. Growth for Evonik will not come from one single new product or plant. It will come from a combination of factors. Launching entire new products and solutions, bringing existing products into new markets, Enhancing our plant utilization and increasing product contribution margins and therefore have an EVDA margin expansion. At the forefront of future sales growth are products developed in our three innovation growth areas. These products are targeting markets which by far outgrow GDP. For example, our biotech platform already This is an incredibly strong basis we have to drive further growth where customers shift to bio-based products in cosmetics, pharma, but also in some industrial applications, such as coatings. The second big pillar is about efficiency. Since the end of 2023, we are tailoring our organization to better suit our business needs and to become more agile, while at the same time keeping our cost base under control. Balancing inflation is the minimum target, and any additional savings are contributions to our targeted earnings increase. The first phase of Evonik Tailormade is almost And we kicked off the second phase of the program mid of this year. It now takes a more holistic approach by integrating all business optimization and administrative programs under one roof. We have strong proof points of our progress. Employee numbers are falling fast. We are more than 700 already this year alone. We announced three side shutdowns this year. This is a decisive net not seen before from us. On top, we are getting divestment funds. The sale of Oxino will be signed in the coming months. Thereafter, Evonik will account for only one-third of the chemical activities at the chemical park in Mahl. For our infrastructure business, called Renect, which is serving Mahl, We will find a new best owner shortly after. Of course, we will go through these processes with all our stakeholders in mind, but especially our employees, and find the best future for these two assets. We will be focusing on what a specialty chemical company like us should be focusing on, namely on our business, on customers, custom solutions and advanced technology segments, to deliver benefits to our customers and to our end users. Infrastructure services shall be better owned by infrastructure specialists or large-scale integrated chemical park owners. We will deploy the divestment proceeds to invest where we see our future. In additives, in biotech, for growth markets. Now, Michael, We take over as we move from increasing earnings to reducing capital employed. Michael, words first.

speaker
Michael
Chief Financial Officer

Thank you, Claus. Welcome to all of you also from my side. As Claus said in the beginning, capital employed is now a bigger focus than before. Starting with capex, you can observe a steady decrease already over the last years. This trend will continue. We see our run rate for CapEx even lower than today at around 700 million euros for the coming years. This is a reflection of the reshaping of our portfolio. Less capital-intensive businesses with higher returns like Editors or Biotech Solutions. So CapEx level below our historic depreciation and amortization is a sound testimonial of our strategy execution. It is clearly not a sign of us under-investing. and after exiting Oxeno and Senect, the CapEx needs will even out further. To bring capital employed down further in the coming years, we will also reduce our networking capital needs. In the last years, we had to take heavy year-end networking capital optimization measures to then end with around 18% of networking capital to sales ratio. Our target is to reach a networking capital to sales ratio of 70% and this is much more balanced throughout the year. To this end, we will, among other measures, also leverage the power of artificial intelligence to further optimize inventory management and improve administrative processes for our payment collection and execution. Moving on to current performance in the third quarter of this year. Our adjusted EBTA rose by 40% to 629 million euros in the third quarter. This is exactly in line with Q2 and our expectations set at the time for Q3. The increase was driven by mainly higher prices in advanced technologies and in our C4 business. Volumes were also up in advanced technologies as well. As anticipated, methionine delivered a strong third quarter with price increases now fully coming through. but also other businesses performed well despite some Asian competitions slowly coming back. For example, we recorded strong volumes for polymers and solid pricing for crosslinkers again. This shows that the strong performance is not just due to slowly vanishing supply chain disruptions. Our results are a clear sign that our customers value our solutions and services as well as our supply reliability. This will not go away again. Cost savings made a good contribution, while higher bonus provisions had an adverse effect. This is as usual mostly visible in the others line, which is more negative than last year. One remark on adjustments. As projected during our Q2 results call, we now did a provision for the second phase of Evonik Taylor made program in Q3. It is a bit over 300 million euros and we expect another high double digit million euro amount to follow in Q4 when all negotiations are finalized. And as already demonstrated in Q2, once again we're able to convert the strong operating performance into cash. For Q3, we improved our free cash flow significantly year over year by more than 20%.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation